Current:Home > reviewsHow well does a new Alzheimer's drug work for those most at risk? -WealthRoots Academy
How well does a new Alzheimer's drug work for those most at risk?
View
Date:2025-04-15 12:33:33
Listen to Short Wave on Spotify, Apple Podcasts and Google Podcasts.
A new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people.
While some saw it as undeniable progress for a disease with no other proven treatment, others urged caution because of severe side effects and the finding of only a "modest" effect. Dr. Jonathan Jackson, Assistant Professor of Neurology at Harvard Medical School, has another concern: the racial and ethnic makeup of the trial.
The clinical trial for lecanemab was the most diverse for an Alzheimer's treatment to date, but it still was not enough to definitively say if the drug is effective for Black people.
"[In] the world's most diverse Alzheimer's trial, a giant trial of 1,800 people that lasted for a much longer time than most trials did, we're still not sure that all of the groups that are at highest risk of Alzheimer's disease actually see any kind of benefit," Jackson, director of the Community Access, Recruitment, and Engagement Research Center, says.
The makers of lecanemab say the trial was able to enroll more Black and Hispanic patients by removing some of the requirements that had been in place for previous trials. They cite tapping into community outreach groups and making it "easy for the patients to enroll into the study, and we made it easy for the patients to actually continue to participate in the study," says Shobha Dhadda, Vice President of Biostatistics and clinical development operations for Neurology at the pharmaceutical company Esai.
The trial enrollment comes close to reaching the racial breakdown of people 65 and older according to the census, but Jackson says that's the wrong goal. Black and Hispanic people, women, and those with a genetic predisposition are all at disproportionately high risk for developing Alzheimer's. Jackson says companies should be overrepresenting these groups in their trials.
"If we continue to study privileged populations ... we're leaving huge questions unanswered about how Alzheimer's works, how it progresses, and what are the significant risk factors," he says. "So when you're designing a study, you should really worry less about the census and more about trying to represent those who are disproportionately affected."
On today's episode, Jonathan and Short Wave co-host Emily Kwong delve into how drug developers can overlook those hardest hit by the disease they're trying to treat.
Have suggestions for what we should cover in future episodes? Email us at [email protected].
This episode was produced by Liz Metzger and edited by Gabriel Spitzer. Anil Oza contributed additional reporting and checked the facts. Patrick Murray was the audio engineer.
veryGood! (47)
Related
- Costco membership growth 'robust,' even amid fee increase: What to know about earnings release
- Road Salts Wash Into Mississippi River, Damaging Ecosystems and Pipes
- Imagining a World Without Fossil Fuels
- Mono Lake Tribe Seeks to Assert Its Water Rights in Call For Emergency Halt of Water Diversions to Los Angeles
- Which apps offer encrypted messaging? How to switch and what to know after feds’ warning
- Micellar Water You’ll Dump Makeup Remover Wipes For From Bioderma, Garnier & More
- In Pennsylvania, Home to the Nation’s First Oil Well, Environmental Activists Stage a ‘People’s Filibuster’ at the Bustling State Capitol
- Encina Chemical Recycling Plant in Pennsylvania Faces Setback: One of its Buildings Is Too Tall
- See you latte: Starbucks plans to cut 30% of its menu
- 20 Top-Rated Deals Under $25 From Amazon Prime Day 2023
Ranking
- US appeals court rejects Nasdaq’s diversity rules for company boards
- Louisiana Regulators Are Not Keeping Up With LNG Boom, Environmentalists Say
- Environmentalists Praise the EPA’s Move to Restrict ‘Forever Chemicals’ in Water and Wonder, What’s Next?
- Senator’s Bill Would Fine Texans for Multiple Environmental Complaints That Don’t Lead to Enforcement
- EU countries double down on a halt to Syrian asylum claims but will not yet send people back
- What Lego—Yes, Lego—Can Teach Us About Avoiding Energy Project Boondoggles
- Ambitious Climate Proposition Faces Fossil Fuel Backlash in El Paso
- Holiday Traditions in the Forest Revive Spiritual Relationships with Nature, and Heal Planetary Wounds
Recommendation
Paige Bueckers vs. Hannah Hidalgo highlights women's basketball games to watch
Apple iPhone from 2007 sells for more than $190,000 at auction
Las Vegas Is Counting on Public Lands to Power its Growth. Is it a Good Idea?
After Cutting Off Water to a Neighboring Community, Scottsdale Proposes a Solution
Trump's 'stop
ESPYS 2023 Red Carpet Fashion: See Every Look as the Stars Arrive
Make Your Life Easier With 25 Problem-Solving Products on Sale For Less Than $21 on Prime Day 2023
Outrage over man who desecrated Quran prompts protesters to set Swedish Embassy in Iraq on fire